Angelman Syndrome Clinical Trials Angelman Syndrome RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

GeneTx and Ultragenyx Announce Positive Interim Phase 1/2 Data on Investigational GTX-102 Demonstrating Improvement in Patients with Angelman Syndrome
SARASOTA, Fla. and NOVATO, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of intrathecally administered GTX-102, an investigational... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 28, 2020 Category: Pharmaceuticals Source Type: clinical trials

Angelman Syndrome Natural History Study
Condition:   Angelman Syndrome Intervention:   Sponsors:   Boston Children’s Hospital;   Food and Drug Administration (FDA);   University of California, San Diego Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 11, 2020 Category: Research Source Type: clinical trials

A Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of RO7248824 In Participants With Angelman Syndrome
Condition:   Angelman Syndrome Intervention:   Drug: RO7248824 Sponsor:   Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 12, 2020 Category: Research Source Type: clinical trials